EVSC ~ Reuters reporting now ~ report dated Dec.

EVSC ~ Reuters reporting now ~ report dated Dec. 12, 2012 ~ Endovasc, Inc. (Endovasc), incorporated on June 10, 1996, is a business development company. The Company assists medical device companies that do not have ready access to capital through conventional financial channels. The Company provides capital and managerial expertise to these companies for the development, marketing and licensing biopharmaceutical products, particularly liposomal drug delivery methods, for the human healthcare industry. Through one of Endovasc's portfolio companies, Liprostin, Inc., Endovasc develops liposomes, which are microscopic cell-like spheres made up of a thin lipid membrane, which surrounds a hollow compartment. The Company’s products include Liprostin, PROStent, Biodegradable Vascular Stents, Biodegradable Ureteral and Prostatic Stents and Endothil-CR. The Company competes with Eli Lilly and Company, Medtronic, Inc., Cordis Corporation, Cook Group Incorporated, Boston Scientific Corporation and Anesiva, Inc.